Insights That Move the GPCR Field Forward

Discovery on Target returns to Boston September 28 to October 1, 2026, with GPCR science woven through the Lead Generation Strategies program. Ahead of the meeting, we spoke with four scientists presenting and teaching this year, from partial agonism to obesity targets to fragment screening against orphan receptors.

An amylin receptor is a calcitonin receptor paired with a RAMP, and in a standard cell line the calcitonin side dominates, so the pharmacology reads as calcitonin, not amylin. Here is why that happens, how a low-expression approach fixes it, and what clean cAMP and β-arrestin readouts across AMY1, AMY2, and AMY3 open up for obesity and diabetes drug discovery.